CSCIF COSCIENS Biopharma Inc. IFRS
Perfumes, Cosmetics & Other Toilet Preparations · OTC · SEC CIK 1113423 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 | 2024Q4*2024-12-31 | 2024Q3*2024-09-30 | 2024Q2*2024-06-30 | 2024Q1*2024-03-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.77M | $1.48M | $2.75M | $1.50M | $3.32M | $1.87M | $2.34M | $2.06M |
| Cost of revenue | $1.16M | $862,000 | $1.77M | $1.06M | $1.27M | $914,000 | $1.52M | $1.15M |
| Gross profit | $609,000 | $621,000 | $974,000 | $443,000 | $2.05M | $957,000 | $819,000 | $904,000 |
| R&D expense | $599,000 | $527,000 | $690,000 | $1.13M | $2.91M | $2.80M | $1.53M | $1.06M |
| SG&A expense | $2.40M | $2.10M | $2.64M | $2.93M | $2.75M | $2.99M | $3.04M | $1.66M |
| Operating income | -$2.39M | -$2.32M | -$2.35M | -$3.62M | -$6.41M | -$6.29M | -$3.75M | -$1.81M |
| Interest expense | $32,000 | $43,000 | $23,000 | $70,000 | $23,000 | $22,000 | $22,000 | $63,000 |
| Pretax income | -$2.17M | -$1.82M | -$2.70M | -$3.65M | -$5.65M | -$5.87M | -$1.90M | -$1.81M |
| Income tax | — | — | $1,000 | — | $1.08M | -$112,000 | -$474,000 | -$412,000 |
| Net income | -$2.18M | -$1.82M | -$2.70M | -$3.65M | -$6.73M | -$5.75M | -$1.42M | -$1.40M |
| EBITDA | -$2.10M | -$2.04M | -$2.07M | -$3.29M | -$6.02M | -$5.81M | -$3.38M | -$1.46M |
| EPS (basic) | — | -0.57 | -0.85 | -1.16 | — | -1.85 | -0.64 | -0.76 |
| EPS (diluted) | — | -0.57 | -0.85 | -1.16 | — | -1.85 | -0.64 | -0.76 |
| Weighted avg. shares (diluted) | — | 3.18M | 3.17M | 3.14M | — | 3.11M | 2.22M | 1.85M |
| Balance sheet | ||||||||
| Cash & equivalents | $7.31M | $8.52M | $9.33M | $13.76M | $16.39M | $20.00M | $27.80M | $3.51M |
| Receivables | $1.26M | $1.60M | $2.78M | $1.86M | $2.36M | $1.89M | $1.24M | $190,000 |
| Inventory | $1.31M | $1.76M | $1.82M | $2.46M | $2.69M | $3.31M | $3.06M | $64,000 |
| Current assets | $11.50M | $13.84M | $16.50M | $20.35M | $23.98M | $28.22M | $33.21M | $31.20M |
| PP&E, netmay include right-of-use assets (IFRS) | $9.81M | $9.89M | $10.92M | $10.66M | $10.97M | $11.81M | $11.50M | $271,000 |
| Intangibles | — | — | — | — | — | $1.81M | $3.33M | — |
| Total assets | $21.43M | $23.86M | $27.56M | $31.14M | $35.07M | $43.77M | $50.05M | $31.79M |
| Current liabilities | $3.61M | $3.98M | $5.53M | $7.06M | $7.22M | $8.17M | $9.90M | $5.25M |
| Total liabilities | $17.59M | $18.78M | $20.46M | $21.00M | $21.91M | $23.75M | $23.82M | $18.82M |
| Shareholders' equity | $3.84M | $5.08M | $7.10M | $10.14M | $13.16M | $20.01M | $26.23M | $19.19M |
| Cash flow statement | ||||||||
| Operating cash flow | -$1.47M | -$676,000 | -$4.45M | -$1.88M | -$3.00M | -$7.78M | -$1.39M | -$2.38M |
| Capital expenditure | $46,000 | -$4,000 | $49,000 | $615,000 | $309,000 | $131,000 | $157,000 | $564,000 |
| Free cash flow | -$1.52M | -$672,000 | -$4.50M | -$2.50M | -$3.31M | -$7.91M | -$1.55M | -$2.94M |
| Investing cash flow | $201,000 | $4,000 | -$48,000 | -$615,000 | -$316,000 | $83,000 | $25.88M | -$564,000 |
| Financing cash flow | -$15,000 | -$85,000 | -$107,000 | -$200,000 | -$202,000 | -$188,000 | -$126,000 | -$94,000 |
| Depreciation & amortization | $289,000 | $287,000 | $287,000 | $325,000 | $392,000 | $479,000 | $377,000 | $359,000 |
| Stock-based compensation | $88,000 | -$21,000 | -$85,000 | $6,000 | $10,000 | $427,000 | $13,000 | $14,000 |
Free plan shows the latest 8 periods; Pro shows all 31 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.